Table 2.
HIV-1 subtype and drug resistance mutations in patients
| Cases | Controls | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| KAF | Subtype | Mutationsa | GSSa | HIV-1 VL | KAF | Subtype | Mutationsa | GSSa | HIV-1 VL |
| 151 | CRF02_AG | – | 0 | 5.38 | 075 | CRF02_AG | – | 0 | 5.08 |
| 083 | CRF02_AG | – | 0 | 5.74 | 124 | CRF02_AG | – | 0 | 5.46 |
| 092 | CRF02_AG | – | 0 | 5.87 | 023 | CRF01_AE | na | na | 5.49 |
| 028 | CRF02_AG | – | 0 | 5.26 | 130 | CRF02_AG/G | – | 0 | 5.73 |
| 090 | G | – | 0 | 4.76 | 033 | A/CRF01_AE | V118I | 0 | 6.02 |
| 056 | G | na | na | 5.33 | 081 | CRF02_AG | – | 0 | 5.39 |
| 071 | CRF02_AG | V108I, V179E | 25 | 5.16 | 078 | CRF02_AG | E138A | 0 | 3.52 |
| 120 | CRF02_AG | – | 0 | 5.65 | 104 | G | V108I | 15 | 5.18 |
| 026 | CRF02_AG | – | 0 | 5.76 | 149 | CRF02_AG | – | 0 | 4.65 |
| 115 | CRF02_AG | – | 0 | 5.09 | 074 | CRF02_AG | – | 0 | 5.73 |
| 031 | CRF02_AG | V90I | 0 | 4.87 | 137 | A/CRF02_AG | – | 0 | 5.28 |
| 061 | CRF02_AG | – | 0 | 5.86 | 010 | CRF02_AG | – | 0 | 6.33 |
| 077 | CRF02_AG | – | 0 | 5.52 | 064 | na | na | na | 6.45 |
| 041 | G | V108IV, E138A, V179EV | 10 | 4.20 | 121 | CRF02_AG | – | 0 | 6.27 |
| 156 | CRF02_AG | – | 0 | 5.54 | 037 | CRF02_AG | – | 0 | 5.49 |
| 011 | CRF02_AG | V90I | 0 | 5.31 | 095 | CRF02_AG | – | 0 | 6.15 |
| 109 | CRF02_AG | – | 0 | 6.08 | 019 | G | – | 0 | 6.16 |
| 200 | na | na | na | na | 024 | CRF02_AG | – | 0 | 4.46 |
KAF, patients ID; Cases, individuals infected with HIV and HBV; Controls, those infected with only HIV; Mutationsa/GSSa, HIV-1 drug resistance mutations/genotypic sensitivity scores (GSS) based on specific ARVs used by patients as determined by the Stanford database (analyzed on July 8, 2014); HIV-1 VL, pre-HAART HIV-1 plasma viral load. Subtypes were determined by the Stanford database
na not available